Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.
Light Horse Therapeutics has raised $62.0M in total funding. The most recent round was Series A. The last funding was announced in January 2025.
Light Horse Therapeutics's investors include AbbVie, Mubadala Capital, Versant Ventures, Bristol-Myers Squibb, Taiho Ventures.
Light Horse Therapeutics is headquartered in San Diego, United States.
Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.
Light Horse Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Light Horse Therapeutics — Funding & Investors." VCBacked, January 9, 2025, https://www.vcbacked.co/company/light-horse-therapeutics. Accessed August 16, 2026.
VCBacked. (2025). Light Horse Therapeutics — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/light-horse-therapeutics
{{cite web |title=Light Horse Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/light-horse-therapeutics |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated